Ji L, Kang ES, Dong X, et al. - By performing this open-label, randomised, active-controlled, 26-week study, researchers compared Gla-300 vs Gla-100 in terms of efficacy and safety in insulin-naïve individuals with type 2 diabetes mellitus (T2DM) in Asia Pacific. They randomized (2:1) insulin-naïve people with T2DM, inadequately controlled with non-insulin antihyperglycaemic drugs, to Gla-300 or Gla-100. The initial daily dose of basal insulin was 0.2 U/kg and at least weekly adjustments were made for 8–12 weeks to a target fasting self-monitored plasma glucose of 4.4–5.6 mmol/L. They found that Gla-300 vs Gla-100 provided a non-inferior glycaemic control and resulted in a similar or lower incidence and proportion of hypoglycaemia in individuals with T2DM in Asia Pacific, these findings strengthen the outcomes in the global EDITION programme.